Sun Pharma to consider ₹15,000 crore NCD issue; board meeting on 12 October

Sun Pharmaceutical Industries is due to place a proposal before its board on October 12, 2026, for non convertible debentures of up to Rs 15,000 crore. The proceeds would fund a bridge loan tied to the acquisition of Organon and Co, making the meeting the next formal governance step in arranging acquisition finance. The material does not specify the debentures' tenor, coupon, security, investor base or issue timetable. Sun Pharma shares last stood at Rs 1,765.30, down 0.9% today, 5.8% over one month and 5.9% over three months, and 12% below their 52 week high.

Debt financing matters primarily through funding certainty, interest expense and leverage. A successful issue may support the bridge loan and reduce near term execution risk around the Organon transaction, but its eventual coupon, maturity and security could determine the pressure on Sun Pharma's cash flows and valuation. The broader Pharma and Healthcare sector has fallen 5.7% over one month but risen 1.2% over three months, while Sun Pharma has declined over both periods. Board approval, disclosed terms and completion on manageable conditions would confirm the funding interpretation. A delay, burdensome terms or failure to complete the acquisition would weaken it, with direct exposure concentrated in Sun Pharma and possible sentiment spillovers across large pharmaceutical companies.